Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
That said, some industry participants still looked to capitalize on anticipated vulnerabilities in their competitors pipelines with meaningful M&A bets such as Eli Lillys $2.3 Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy.
Let's personalize your content